AtriCure (ATRC) investor relations material

Product innovation and market penetration

• Flex Mini, a new clip product 60% smaller than competitors, drove 18.5% Q3 growth and reached 30% system penetration within months, outpacing previous launches.

• Flex Mini's design offers better visibility and ease of use, with strong patent protection on fabric and closure mechanisms.

• ASP for Flex Mini is $2,250, higher than previous models, while a low-cost option remains available for price-sensitive customers.

• Next-generation V clip, also 60% smaller, is planned for early 2027.

Encompass and clinical trial updates

• Encompass clamp reduced ablation procedure times from 30-40 minutes to under 10, now over 50% of U.S. revenue.

• Box No AF trial aims to reduce post-op AFib from 35-40% to below 10%, with initial data expected in early 2028.

• LEAPS trial data is not expected until the end of the decade, but enrollment and event accumulation are ahead of schedule.

Pain management business expansion

• cryoSPHERE MAX is driving growth, especially in thoracotomy and now sternotomy, by halving freeze times and improving adoption.

• The XT device targets 90,000 lower limb amputations in the U.S., with a $3,500 ASP, and is expected to become meaningful beyond 2026.

• Total addressable markets: 150,000 thoracic, 250,000 sternotomy, and 90,000 amputation cases annually in the U.S.